Literature DB >> 17413976

Difficulties in assessing the depth of myometrial invasion in endometrial carcinoma.

Asya Ali1, Destin Black, Robert A Soslow.   

Abstract

The depth of myometrial invasion (DMI) is one of the most important prognostic indicators and determinants of therapy in endometrial cancer. There are well-documented problems in recognizing DMI. We examined 100 previously diagnosed endometrioid endometrial carcinomas in hysterectomy specimens, reassessed DMI, and explored morphological features that complicated appraisal of myometrial invasion. The DMI was different from the original measurement in 29% of cases. Twelve percent of all cases (40% of cases with measurement discrepancies) involved differences in the assignment of invasion categories (noninvasive, < or =50% myometrial invasion, and >50% myometrial invasion). Nearly all endometrial cancers originally diagnosed as invasive were considered noninvasive on review. We examined whether the distribution of stromal metaplasia, noninvasive patterns (exophytic tumors, irregular endomyometrial junctions, and adenomyosis), and myometrial invasion patterns were different in cases with and without measurement discrepancies. Irregular endomyometrial junctions, exophytic tumors, and adenomyosis tended to coexist and were more common in the cases with DMI discrepancies. Although there seemed to be a relationship between smooth muscle metaplasia and exophytic tumors, it did not appear that smooth muscle metaplasia was significantly more common in cases with measurement difficulties. However, cases with extensive smooth muscle metaplasia posed problems with assessment of myometrial invasion. Patterns of myometrial invasion other than the conventional destructive pattern were sufficiently uncommon as to not impact on DMI measurement in large numbers of cases. Measuring the DMI is usually uncomplicated, but additional scrutiny should be paid to cases involving exophytic tumors, irregular endomyometrial junctions, adenomyosis, and extensive stromal smooth muscle metaplasia.

Entities:  

Mesh:

Year:  2007        PMID: 17413976     DOI: 10.1097/01.pgp.0000233165.56385.0b

Source DB:  PubMed          Journal:  Int J Gynecol Pathol        ISSN: 0277-1691            Impact factor:   2.762


  11 in total

Review 1.  Practical issues related to uterine pathology: staging, frozen section, artifacts, and Lynch syndrome.

Authors:  Robert A Soslow
Journal:  Mod Pathol       Date:  2016-01       Impact factor: 7.842

2.  ESGO/ESTRO/ESP Guidelines for the management of patients with endometrial carcinoma.

Authors:  Nicole Concin; Carien L Creutzberg; Ignace Vergote; David Cibula; Mansoor Raza Mirza; Simone Marnitz; Jonathan A Ledermann; Tjalling Bosse; Cyrus Chargari; Anna Fagotti; Christina Fotopoulou; Antonio González-Martín; Sigurd F Lax; Domenica Lorusso; Christian Marth; Philippe Morice; Remi A Nout; Dearbhaile E O'Donnell; Denis Querleu; Maria Rosaria Raspollini; Jalid Sehouli; Alina E Sturdza; Alexandra Taylor; Anneke M Westermann; Pauline Wimberger; Nicoletta Colombo; François Planchamp; Xavier Matias-Guiu
Journal:  Virchows Arch       Date:  2021-02       Impact factor: 4.064

3.  Evaluation of tumor-free distance and depth of myometrial invasion as prognostic factors in endometrial cancer.

Authors:  Raoudha Doghri; Salma Chaabouni; Yoldez Houcine; Lamia Charfi; Nadia Boujelbene; Maha Driss; Karima Mrad
Journal:  Mol Clin Oncol       Date:  2018-05-16

4.  Type II endometrial cancers: A case series.

Authors:  Flora D Lobo; Eliz Thomas
Journal:  J Midlife Health       Date:  2016 Apr-Jun

5.  Reproducibility of measurement of myometrial invasion in endometrial carcinoma.

Authors:  Louis J M van der Putten; Koen van de Vijver; Carla Bartosch; Ben Davidson; Sonia Gatius; Xavier Matias-Guiu; W Glenn McCluggage; Gemma Toledo; Anneke A M van der Wurff; Johanna M A Pijnenborg; Leon F A G Massuger; Johan Bulten
Journal:  Virchows Arch       Date:  2016-10-27       Impact factor: 4.064

6.  Characterization of the Endometrial MSC Marker Ectonucleoside Triphosphate Diphosphohydrolase-2 (NTPDase2/CD39L1) in Low- and High-Grade Endometrial Carcinomas: Loss of Stromal Expression in the Invasive Phenotypes.

Authors:  Aitor Rodríguez-Martínez; Carla Trapero; August Vidal; Josep Maria Piulats; Inmaculada Gómez de Aranda; Jean Sévigny; Maria Eulàlia Fernández-Montolí; Jordi Ponce; Xavier Matias-Guiu; Mireia Martín-Satué
Journal:  J Pers Med       Date:  2021-04-22

7.  MRI-assessed tumor-free distance to serosa predicts deep myometrial invasion and poor outcome in endometrial cancer.

Authors:  Julie Andrea Dybvik; Kristine E Fasmer; Sigmund Ytre-Hauge; Jenny Hild Aase Husby; Øyvind O Salvesen; Ingunn Marie Stefansson; Camilla Krakstad; Jone Trovik; Ingfrid S Haldorsen
Journal:  Insights Imaging       Date:  2022-01-08

8.  Microcystic, elongated, and fragmented pattern of invasion in relation to histopathologic and clinical prognostic factors in endometrioid endometrial adenocarcinoma.

Authors:  M Murat Naki; Gülbin Oran; Seza Ümit Tetikkurt; Cavide Fatma Sönmez; İlknur Türkmen; Faruk Köse
Journal:  J Turk Ger Gynecol Assoc       Date:  2017-09-01

9.  IFITM1 Is Superior to CD10 as a Marker of Endometrial Stroma in the Evaluation of Myometrial Invasion by Endometrioid Adenocarcinoma.

Authors:  Aurelia Busca; Bojana Djordjevic; Ana Giassi; Carlos Parra-Herran
Journal:  Am J Clin Pathol       Date:  2016-03-21       Impact factor: 2.493

10.  Peritumoral Enhancement for the Evaluation of Myometrial Invasion in Low-Risk Endometrial Carcinoma on Dynamic Contrast-Enhanced MRI.

Authors:  Tingting Cui; Feng Shi; Bei Gu; Yanfang Jin; Jinsong Guo; Chao Zhang; Jie Ren; Yunlong Yue
Journal:  Front Oncol       Date:  2022-01-17       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.